[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f4CfcQVUMgFzH0_lGNWyZuTyHP1pdoxKhRhv8A4py6LE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":30,"phaseBuckets":50,"rows":57},"Great Ormond Street Hospital for Children NHS Foundation Trust",[4],82,false,13,2,18800,3,61,[14,16,18,20,22,24,26,28],{"name":15,"count":11},"Epilepsy",{"name":17,"count":11},"Cystic Fibrosis",{"name":19,"count":9},"Haemodiafiltration",{"name":21,"count":9},"Duchenne Muscular Dystrophy",{"name":23,"count":9},"Becker Muscular Dystrophy",{"name":25,"count":9},"Child",{"name":27,"count":9},"Dilated Cardiomyopathy",{"name":29,"count":9},"Moyamoya",[31,36,41,46],{"nctId":32,"briefTitle":33,"date":34,"intervention":35},"NCT05942599","Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation","2026-06-01","Cryopreserved BE CAR33 T Cells",{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03601286","Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency","2026-08","Lentiviral vector transduced CD34+ cells",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06421103","Micro-dosing Indocyanine Green (ICG) in Children","2028-08","Indocyanine Green",{"nctId":47,"briefTitle":48,"date":49,"intervention":40},"NCT05207657","Lentiviral Gene Therapy for p47 AR-CGD","2029-04-01",[51,52,53,54,55,56],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[58,88,110,134,162,189,228,250,275,299,317,342,368,393,417,435,459,484,509,533,557,581],{"intervention":40,"totalTrials":9,"cells":59},{"EARLY_PHASE1":60,"PHASE1":63,"PHASE2":74,"PHASE3":82,"PHASE4":84,"NA":86},{"trials":61,"activeCount":62},[],0,{"trials":64,"activeCount":73,"soonestReadout":39},[65],{"nctId":37,"briefTitle":38,"status":66,"phases":67,"primaryCompletion":39,"completion":39,"start":68,"enrollment":69,"conditions":70,"interventions":72},"RECRUITING",[52],"2018-12-21",5,[71],"Severe Combined Immunodeficiency, X-Linked",[40],1,{"trials":75,"activeCount":73,"soonestReadout":49},[76],{"nctId":47,"briefTitle":48,"status":66,"phases":77,"primaryCompletion":49,"completion":49,"start":78,"enrollment":69,"conditions":79,"interventions":81},[52,53],"2023-03-20",[80],"P47-Phox, Deficiency of",[40],{"trials":83,"activeCount":62},[],{"trials":85,"activeCount":62},[],{"trials":87,"activeCount":62},[],{"intervention":35,"totalTrials":73,"cells":89},{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":108},{"trials":91,"activeCount":62},[],{"trials":93,"activeCount":73,"soonestReadout":34},[94],{"nctId":32,"briefTitle":33,"status":95,"phases":96,"primaryCompletion":34,"completion":34,"start":97,"enrollment":98,"conditions":99,"interventions":101},"ACTIVE_NOT_RECRUITING",[52],"2023-07-21",10,[100],"Relapsed Acute Myeloid Leukaemia",[35],{"trials":103,"activeCount":62},[],{"trials":105,"activeCount":62},[],{"trials":107,"activeCount":62},[],{"trials":109,"activeCount":62},[],{"intervention":45,"totalTrials":73,"cells":111},{"EARLY_PHASE1":112,"PHASE1":114,"PHASE2":116,"PHASE3":118,"PHASE4":120,"NA":122},{"trials":113,"activeCount":62},[],{"trials":115,"activeCount":62},[],{"trials":117,"activeCount":62},[],{"trials":119,"activeCount":62},[],{"trials":121,"activeCount":62},[],{"trials":123,"activeCount":73,"soonestReadout":44},[124],{"nctId":42,"briefTitle":43,"status":66,"phases":125,"primaryCompletion":44,"completion":44,"start":126,"enrollment":127,"conditions":128,"interventions":133},[56],"2024-06",90,[129,130,131,132],"Perfusion","Fluorescence Imaging","Gastrointestinal Tract Disorders","Genitourinary Disease",[45],{"intervention":135,"totalTrials":73,"cells":136},"Propofol 2%",{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":160},{"trials":138,"activeCount":62},[],{"trials":140,"activeCount":62},[],{"trials":142,"activeCount":62},[],{"trials":144,"activeCount":62},[],{"trials":146,"activeCount":62},[147],{"nctId":148,"briefTitle":149,"status":150,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":159},"NCT01932424","Blood Propofol Concentrations in Children During Spinal Surgery","COMPLETED",[55],"2013-07","2013-01",20,[156,157,158],"Spine Deformities","Idiopathic Scoliosis","Neuromuscular Dystrophy",[135],{"trials":161,"activeCount":62},[],{"intervention":163,"totalTrials":73,"cells":164},"Montelukast",{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":185,"NA":187},{"trials":166,"activeCount":62},[],{"trials":168,"activeCount":62},[],{"trials":170,"activeCount":62},[],{"trials":172,"activeCount":62},[173],{"nctId":174,"briefTitle":175,"status":176,"phases":177,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":184},"NCT04351698","SMILES: Study of Montelukast in Sickle Cell Disease","UNKNOWN",[53,54],"2024-09-30","2023-10-16",200,[182,183],"Anemia, Sickle Cell","Sleep-Disordered Breathing",[163],{"trials":186,"activeCount":62},[],{"trials":188,"activeCount":62},[],{"intervention":190,"totalTrials":9,"cells":191},"Busulfan",{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":222,"PHASE4":224,"NA":226},{"trials":193,"activeCount":62},[],{"trials":195,"activeCount":62},[],{"trials":197,"activeCount":62},[198,211],{"nctId":199,"briefTitle":200,"status":150,"phases":201,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":208},"NCT01380990","Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency",[52,53],"2019-12-23","2012-11-15",36,[206,207],"Adenosine Deaminase Deficiency","Severe Combined Immunodeficiencies (SCID)",[209,190,210],"Infusion of autologous EFS-ADA LV CD34+ cells","Peg-Ada",{"nctId":212,"briefTitle":213,"status":150,"phases":214,"primaryCompletion":215,"completion":216,"start":217,"enrollment":8,"conditions":218,"interventions":220},"NCT03765632","Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID",[52,53],"2021-09-13","2022-09-28","2018-01-03",[219],"Severe Combined Immunodeficiency Due to ADA Deficiency",[221,190,210],"Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells",{"trials":223,"activeCount":62},[],{"trials":225,"activeCount":62},[],{"trials":227,"activeCount":62},[],{"intervention":210,"totalTrials":9,"cells":229},{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":244,"PHASE4":246,"NA":248},{"trials":231,"activeCount":62},[],{"trials":233,"activeCount":62},[],{"trials":235,"activeCount":62},[236,240],{"nctId":199,"briefTitle":200,"status":150,"phases":237,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":238,"interventions":239},[52,53],[206,207],[209,190,210],{"nctId":212,"briefTitle":213,"status":150,"phases":241,"primaryCompletion":215,"completion":216,"start":217,"enrollment":8,"conditions":242,"interventions":243},[52,53],[219],[221,190,210],{"trials":245,"activeCount":62},[],{"trials":247,"activeCount":62},[],{"trials":249,"activeCount":62},[],{"intervention":251,"totalTrials":73,"cells":252},"pCCLchimGp91s lentiviral vector transduced CD34+ cells",{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":269,"PHASE4":271,"NA":273},{"trials":254,"activeCount":62},[],{"trials":256,"activeCount":62},[],{"trials":258,"activeCount":62},[259],{"nctId":260,"briefTitle":261,"status":262,"phases":263,"primaryCompletion":264,"completion":264,"start":265,"enrollment":62,"conditions":266,"interventions":268},"NCT01381003","Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease (X-CGD)","WITHDRAWN",[52,53],"2016-11","2011-11",[267],"Granulomatous Disease, Chronic, X-linked, Variant",[251],{"trials":270,"activeCount":62},[],{"trials":272,"activeCount":62},[],{"trials":274,"activeCount":62},[],{"intervention":276,"totalTrials":73,"cells":277},"HSVTK retrovirally-transduced donor T lymphocytes",{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":293,"PHASE4":295,"NA":297},{"trials":279,"activeCount":62},[],{"trials":281,"activeCount":62},[],{"trials":283,"activeCount":62},[284],{"nctId":285,"briefTitle":286,"status":287,"phases":288,"primaryCompletion":153,"completion":153,"start":289,"enrollment":9,"conditions":290,"interventions":292},"NCT01204502","Suicide Gene Therapy Trial","TERMINATED",[52,53],"2011-01",[291],"Haploidentical Stem Cell Transplantation",[276],{"trials":294,"activeCount":62},[],{"trials":296,"activeCount":62},[],{"trials":298,"activeCount":62},[],{"intervention":209,"totalTrials":73,"cells":300},{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":311,"PHASE4":313,"NA":315},{"trials":302,"activeCount":62},[],{"trials":304,"activeCount":62},[],{"trials":306,"activeCount":62},[307],{"nctId":199,"briefTitle":200,"status":150,"phases":308,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":309,"interventions":310},[52,53],[206,207],[209,190,210],{"trials":312,"activeCount":62},[],{"trials":314,"activeCount":62},[],{"trials":316,"activeCount":62},[],{"intervention":318,"totalTrials":73,"cells":319},"Bumetanide",{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":321,"activeCount":62},[],{"trials":323,"activeCount":62},[],{"trials":325,"activeCount":62},[326],{"nctId":327,"briefTitle":328,"status":150,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":335},"NCT01434225","NEMO1:NEonatal Seizure Using Medication Off-patent",[52,53],"2013-06","2011-08",14,[334],"Neonatal Seizures",[318],{"trials":337,"activeCount":62},[],{"trials":339,"activeCount":62},[],{"trials":341,"activeCount":62},[],{"intervention":343,"totalTrials":73,"cells":344},"Selumetinib",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":362,"PHASE4":364,"NA":366},{"trials":346,"activeCount":62},[],{"trials":348,"activeCount":62},[],{"trials":350,"activeCount":62},[351],{"nctId":352,"briefTitle":353,"status":150,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":332,"conditions":357,"interventions":361},"NCT03326388","Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours",[52,53],"2024-02-14","2019-09-26",[358,359,360],"Neurofibromatosis Type 1","Plexiform Neurofibroma","Optic Nerve Glioma",[343],{"trials":363,"activeCount":62},[],{"trials":365,"activeCount":62},[],{"trials":367,"activeCount":62},[],{"intervention":369,"totalTrials":73,"cells":370},"90-Yttrium-labelled anti-CD66 monoclonal antibody",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":387,"PHASE4":389,"NA":391},{"trials":372,"activeCount":62},[],{"trials":374,"activeCount":62},[],{"trials":376,"activeCount":62},[377],{"nctId":378,"briefTitle":379,"status":176,"phases":380,"primaryCompletion":381,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":386},"NCT04856215","90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia",[53],"2025-09-30","2023-09-29",25,[385],"Leukemia",[369],{"trials":388,"activeCount":62},[],{"trials":390,"activeCount":62},[],{"trials":392,"activeCount":62},[],{"intervention":394,"totalTrials":73,"cells":395},"Intravenous infusion of transduced cells",{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":411,"PHASE4":413,"NA":415},{"trials":397,"activeCount":62},[],{"trials":399,"activeCount":62},[],{"trials":401,"activeCount":62},[402],{"nctId":403,"briefTitle":404,"status":150,"phases":405,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":410},"NCT01279720","Gene Therapy ADA Deficiency",[52,53],"2013-11","2003-10",8,[206],[394],{"trials":412,"activeCount":62},[],{"trials":414,"activeCount":62},[],{"trials":416,"activeCount":62},[],{"intervention":221,"totalTrials":73,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":429,"PHASE4":431,"NA":433},{"trials":420,"activeCount":62},[],{"trials":422,"activeCount":62},[],{"trials":424,"activeCount":62},[425],{"nctId":212,"briefTitle":213,"status":150,"phases":426,"primaryCompletion":215,"completion":216,"start":217,"enrollment":8,"conditions":427,"interventions":428},[52,53],[219],[221,190,210],{"trials":430,"activeCount":62},[],{"trials":432,"activeCount":62},[],{"trials":434,"activeCount":62},[],{"intervention":436,"totalTrials":73,"cells":437},"One 20cm2\u002F10cm2 autologous skin sheet graft",{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":451,"PHASE3":453,"PHASE4":455,"NA":457},{"trials":439,"activeCount":62},[],{"trials":441,"activeCount":62},[442],{"nctId":443,"briefTitle":444,"status":176,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":69,"conditions":448,"interventions":450},"NCT01545323","Gene Therapy for Netherton Syndrome",[52],"2018-04","2014-04",[449],"Netherton Syndrome",[436],{"trials":452,"activeCount":62},[],{"trials":454,"activeCount":62},[],{"trials":456,"activeCount":62},[],{"trials":458,"activeCount":62},[],{"intervention":460,"totalTrials":73,"cells":461},"Cryopreserved BE CAR7 T cells",{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":482},{"trials":463,"activeCount":62},[],{"trials":465,"activeCount":62},[466],{"nctId":467,"briefTitle":468,"status":176,"phases":469,"primaryCompletion":470,"completion":471,"start":472,"enrollment":98,"conditions":473,"interventions":475},"NCT05397184","Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7)",[52],"2024-04-01","2025-02-28","2022-04-19",[474],"Relapsed\u002FRefractory T-cell Acute Lymphoid Leukaemia",[460],{"trials":477,"activeCount":62},[],{"trials":479,"activeCount":62},[],{"trials":481,"activeCount":62},[],{"trials":483,"activeCount":62},[],{"intervention":485,"totalTrials":73,"cells":486},"PBLTT52CAR19",{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":501,"PHASE3":503,"PHASE4":505,"NA":507},{"trials":488,"activeCount":62},[],{"trials":490,"activeCount":62},[491],{"nctId":492,"briefTitle":493,"status":150,"phases":494,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":500},"NCT04557436","TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)",[52],"2024-03-05","2020-08-12",9,[499],"B Acute Lymphoblastic Leukemia",[485],{"trials":502,"activeCount":62},[],{"trials":504,"activeCount":62},[],{"trials":506,"activeCount":62},[],{"trials":508,"activeCount":62},[],{"intervention":510,"totalTrials":73,"cells":511},"Treosulfan",{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":518,"PHASE4":520,"NA":522},{"trials":513,"activeCount":62},[],{"trials":515,"activeCount":62},[],{"trials":517,"activeCount":62},[],{"trials":519,"activeCount":62},[],{"trials":521,"activeCount":62},[],{"trials":523,"activeCount":62},[524],{"nctId":525,"briefTitle":526,"status":150,"phases":527,"primaryCompletion":528,"completion":528,"start":529,"enrollment":12,"conditions":530,"interventions":532},"NCT02048800","Treosulfan Pharmacokinetics in Children Undergoing Allogeneic HSCT",[],"2017-07-31","2014-03",[531],"Allogeneic Haematopoietic Stem Cell Transplantation",[510],{"intervention":534,"totalTrials":73,"cells":535},"stem cell",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":544,"NA":546},{"trials":537,"activeCount":62},[],{"trials":539,"activeCount":62},[],{"trials":541,"activeCount":62},[],{"trials":543,"activeCount":62},[],{"trials":545,"activeCount":62},[],{"trials":547,"activeCount":62},[548],{"nctId":549,"briefTitle":550,"status":150,"phases":551,"primaryCompletion":552,"completion":553,"start":554,"enrollment":98,"conditions":555,"interventions":556},"NCT02479776","A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure",[56],"2015-01","2015-03","2008-05",[27],[534],{"intervention":558,"totalTrials":73,"cells":559},"pH Stat",{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":561,"activeCount":62},[],{"trials":563,"activeCount":62},[],{"trials":565,"activeCount":62},[],{"trials":567,"activeCount":62},[],{"trials":569,"activeCount":62},[],{"trials":571,"activeCount":62},[572],{"nctId":573,"briefTitle":574,"status":176,"phases":575,"primaryCompletion":576,"start":577,"enrollment":154,"conditions":578,"interventions":580},"NCT02358382","The Management of Systemic-Pulmonary Collateral Blood Flow in Cyanotic Children During Cardiopulmonary Bypass - Pilot Study",[56],"2017-07","2016-03",[579],"Heart Defects, Congenital",[558],{"intervention":582,"totalTrials":73,"cells":583},"Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre",{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":592,"NA":594},{"trials":585,"activeCount":62},[],{"trials":587,"activeCount":62},[],{"trials":589,"activeCount":62},[],{"trials":591,"activeCount":62},[],{"trials":593,"activeCount":62},[],{"trials":595,"activeCount":62},[596],{"nctId":597,"briefTitle":598,"status":176,"phases":599,"primaryCompletion":600,"completion":600,"start":601,"enrollment":73,"conditions":602,"interventions":604},"NCT01175239","Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)",[56],"2018-12","2011-04",[603],"X-linked Severe Combined Immunodeficiency",[582]]